½ÃÀ庸°í¼­
»óǰÄÚµå
1618510

¹éÇ÷±¸ ¼ººÐ äÁý¼ú ½ÃÀå : À¯Çü, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Leukapheresis Market by Type (Leukapheresis Devices, Leukapheresis Disposables), Application (Research Applications, Therapeutic Applications), End-User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 189 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¹éÇ÷±¸ ¼ººÐ äÁý¼ú ½ÃÀåÀº 2023³â¿¡ 5,621¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 6,162¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 9.71%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 1¾ï 758¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Ç÷¾×¿¡¼­ ¹éÇ÷±¸¸¦ ºÐ¸®Çϴ Ư¼öÇÑ ÀýÂ÷ÀÎ ¹éÇ÷±¸ Á¦°Å ¿ä¹ýÀº ƯÈ÷ ¹éÇ÷º´ ¹× ¸²ÇÁÁ¾°ú °°Àº Áúº´ÀÇ Ä¡·á¿Í CAR T ¼¼Æ÷ ¿ä¹ý°ú °°Àº ÷´Ü Ä¡·á¸¦ À§ÇÑ ¼¼Æ÷¸¦ äÃëÇϱâ À§ÇØ Ä¡·á ¹× ¿¬±¸ ºÐ¾ß¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ±× Çʿ伺Àº ÁÖ·Î Áï°¢ÀûÀÎ Ä¡·á °³ÀÔ°ú ±Þ¼ºÀåÇϰí ÀÖ´Â ¼¼Æ÷ ±â¹Ý ¿¬±¸¿¡¼­ ¼¼Æ÷¸¦ ¹è¾çÇϱâ À§ÇÑ Á¤È®ÇÑ Ç÷¾× ¼ººÐ ºÐ¸®ÀÇ Çʿ伺¿¡¼­ ºñ·ÔµË´Ï´Ù. ¹éÇ÷±¸ Á¦°Å ¿ä¹ýÀÇ ¿ëµµ´Â ÀÓ»ó, »ó¾÷ ¹× ¿¬±¸ ºÐ¾ß¿¡ °ÉÃÄ ÀÖÀ¸¸ç, ÃÖÁ¾ »ç¿ëó´Â º´¿ø, ¿¬±¸ ±â°ü ¹× »ý¸í °øÇÐ ±â¾÷ÀÔ´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº Ç÷¾× °ü·Ã Áúȯ Áõ°¡, ¼¼Æ÷ ±â¹Ý Ä¡·á¹ýÀÇ ¹ßÀü, °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡ÀÔ´Ï´Ù. »õ·Î¿î ºñÁî´Ï½º ±âȸ´Â ¼¼Æ÷¹è¾ç ±â¼ú Çâ»ó°ú °øÁ¤ ÃÖÀûÈ­¸¦ À§ÇÑ AI ÅëÇÕ È°¿ë¿¡ ÀÖ½À´Ï´Ù. ¼¼Æ÷Ä¡·á¿¡ ÃÊÁ¡À» ¸ÂÃá ¹ÙÀÌ¿ÀÅ×Å© ½ºÅ¸Æ®¾÷ÀÇ ±ÞÁõÀº ÀáÀçÀûÀÎ ½ÃÀå È®´ë °¡´É¼ºÀ» ´õ¿í ºÎ°¢½Ã۰í ÀÖ½À´Ï´Ù. ±×·¯³ª ³ôÀº ½Ã¼ú ºñ¿ë, º¹ÀâÇÑ ±ÔÁ¦, °³¹ßµµ»ó±¹¿¡¼­ÀÇ ³·Àº ÀÎÁöµµ µîÀÌ ¹®Á¦Á¡À¸·Î ÁöÀûµÇ°í ÀÖ½À´Ï´Ù. ¹éÇ÷±¸ Á¦°Å Ä¡·á ÀåºñÀÇ ÀÚµ¿È­ ¹× È¿À²È­, ±âÁõÀÚ ¾ÈÀü ÇÁ·ÎÅäÄÝ °³¼±, ¿î¿µ ºñ¿ë Àý°¨ µî Çõ½ÅÀÇ ±âȸ°¡ Á¸ÀçÇÕ´Ï´Ù. ÀÌ ½ÃÀåÀº ¿ªµ¿ÀûÀ̸ç, ºü¸¥ ±â¼ú ¹ßÀü°ú ÀÇ·á Á¦°ø¾÷ü¿Í »ý¸í°øÇÐ ±â¾÷ °£ÀÇ Çù¾÷À» Ư¡À¸·Î ÇÕ´Ï´Ù. °úÁ¦¿¡µµ ºÒ±¸Çϰí, ¾ÆÆç·¹½Ã½º ±â¼úÀÇ ¹üÀ§¿Í È¿À²¼ºÀ» È®´ëÇϱâ À§ÇÑ ±¤¹üÀ§ÇÑ R&D ÅõÀÚ¿Í ºÎ¹® °£ ÆÄÆ®³Ê½ÊÀº ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷µéÀº ȯÀÚ ¼±Åà Àü·«À» Á¤±³È­Çϰí Ä¡·á °á°ú¸¦ °³ÀÎÈ­Çϱâ À§ÇØ µ¥ÀÌÅÍ ºÐ¼®°ú ¸Ó½Å·¯´×À» ÅëÇÑ Çõ½ÅÀ» ÅëÇØ ¹ßÀüÇÏ´Â Á¤¹ÐÀÇ·á ºÎ¹®¿¡ ÀÚº»À» ÅõÀÚÇÒ ¼ö ÀÖ½À´Ï´Ù. ÇâÈÄ ¿¬±¸´Â ºñ¿ë È¿À²ÀûÀ̰í È®À强ÀÌ ³ôÀº ±â¼ú, ±×¸®°í ¾ÆÁ÷ º¸±ÞµÇÁö ¾ÊÀº ½ÃÀå¿¡¼­ ÀÎÁöµµ¸¦ ³ôÀ̱â À§ÇÑ ±¤¹üÀ§ÇÑ ±³À° ÀÌ´Ï¼ÅÆ¼ºê¿¡ ÃÊÁ¡À» ¸ÂÃâ ¼ö ÀÖÀ» °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ½ÃÀåÀÌ ÀÌ·¯ÇÑ º¹ÀâÇÑ »óȲÀ» ÇìÃÄ ³ª°¡±â À§Çؼ­´Â ½ÅÈï±¹¿¡¼­ÀÇ Àü·«Àû Æ÷Áö¼Å´×, ±â¼ú·Â °­È­, º¯È­ÇÏ´Â ±ÔÁ¦ ±âÁØÀ» ÁؼöÇÏ´Â °ÍÀÌ Áö¼Ó °¡´ÉÇÑ ¼ºÀåÀ» À§ÇØ ¸Å¿ì Áß¿äÇÒ °ÍÀÔ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023³â) 5,621¸¸ ´Þ·¯
ÃßÁ¤³â(2024³â) 6,162¸¸ ´Þ·¯
¿¹Ãø³â(2030³â) 1¾ï 758¸¸ ´Þ·¯
CAGR(%) 9.71%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ¹éÇ÷±¸ Á¦°Å ¿ä¹ý ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®À» °ø°³ÇÕ´Ï´Ù.

¹éÇ÷±¸ Á¦°Å ¿ä¹ý ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«Àû ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¾Ï Ä¡·á Àû¿ë È®´ë
    • ÀÓ»ó ¿¬±¸¿¡¼­ÀÇ ¹éÇ÷±¸ Á¦°Å ¿ä¹ý¿¡ ´ëÇÑ ¼ö¿ä
    • ÇåÇ÷¿¡ ´ëÇÑ ³ë·Â Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ³ôÀº ó¸® ºñ¿ë
  • ½ÃÀå ±âȸ
    • ¿¬±¸ °³¹ß Ȱµ¿¿¡ ´ëÇÑ ÁýÁß°ú ÅõÀÚ
    • CAR ¶Ç´Â ÀÔ¾ç ¼¼Æ÷ Ä¡·áÀÇ ¹éÇ÷±¸ Á¦°Å ¿ä¹ý
  • ½ÃÀå °úÁ¦
    • ºÒÄè°¨, ¹ßÀû, Ÿ¹Ú»ó µî ¹éÇ÷±¸ Á¦°Å ¿ä¹ý°ú °ü·ÃµÈ ÀáÀçÀûÀÎ ¹®Á¦µé

Porter's Five Forces: ¹éÇ÷±¸ Á¦°Å ¿ä¹ý ½ÃÀå Ž»öÀ» À§ÇÑ Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ¹éÇ÷±¸ Á¦°Å ¿ä¹ý ½ÃÀå °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â µ¥ Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. PorterÀÇ Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀïÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ¸ð»öÇϱâ À§ÇÑ ¸íÈ®ÇÑ ¹æ¹ýÀ» ¼³¸íÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» º¸¿ÏÇϰí, ÀáÀçÀû µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¹éÇ÷±¸ Á¦°Å ¿ä¹ý ½ÃÀå¿¡¼­ÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¹éÇ÷±¸ Á¦°Å ¿ä¹ý ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ ´ã°í ÀÖÀ¸¸ç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀ̰í Àû±ØÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ¹éÇ÷±¸ Á¦°Å ¿ä¹ý ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

¹éÇ÷±¸ Á¦°Å ¿ä¹ý ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ¼¼ºÐÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º: ¹éÇ÷±¸ Á¦°Å ¿ä¹ý ½ÃÀå¿¡¼­°ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¹éÇ÷±¸ Á¦°Å ¿ä¹ý ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÒ ¼ö ÀÖ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ: ¹éÇ÷±¸ Á¦°Å ¿ä¹ý ½ÃÀå¿¡¼­ ¼º°øÀÇ ±æÀ» ±×¸³´Ï´Ù.

¹éÇ÷±¸ Á¦°Å ¿ä¹ý ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ ü°è¸¦ ±¸ÃàÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÎ¹®¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·ÂÀ» Æò°¡ÇÕ´Ï´Ù.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÎ¹®ÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» ±â¼úÇϰí ÀÖ½À´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, »ê¾÷ÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ, ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ï Á¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
    • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
    • Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®
      • Á¤Ä¡Àû
      • °æÁ¦Àû
      • »çȸÀû
      • ±â¼úÀû
      • ¹ýÀû
      • ȯ°æÀû

    Á¦6Àå ¹éÇ÷±¸ ¼ººÐ äÁý¼ú ½ÃÀå : À¯Çüº°

    • ¼Ò°³
    • ÀåÄ¡
      • ¿ø½ÉºÐ¸®ÀåÄ¡
      • ¸· ºÐ¸® ÀåÄ¡
    • ¼Ò¸ðǰ

    Á¦7Àå ¹éÇ÷±¸ ¼ººÐ äÁý¼ú ½ÃÀå : ¿ëµµº°

    • ¼Ò°³
    • ¿¬±¸ ¿ëµµ
    • Ä¡·á ¿ëµµ

    Á¦8Àå ¹éÇ÷±¸ ¼ººÐ äÁý¼ú ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

    • ¼Ò°³
    • Çмú¿¬±¸±â°ü
    • Ç÷¾× ¼ººÐ °ø±ÞÀÚ¿Í Ç÷¾× ¼¾ÅÍ
    • °è¾à ¿¬±¸ ±â°ü
    • º´¿ø°ú ¼öÇ÷ ¼¾ÅÍ
    • Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷

    Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ ¹éÇ÷±¸ ¼ººÐ äÁý¼ú ½ÃÀå

    • ¼Ò°³
    • ¾Æ¸£ÇîÆ¼³ª
    • ºê¶óÁú
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
    • ¹Ì±¹

    Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¹éÇ÷±¸ ¼ººÐ äÁý¼ú ½ÃÀå

    • ¼Ò°³
    • È£ÁÖ
    • Áß±¹
    • Àεµ
    • Àεµ³×½Ã¾Æ
    • ÀϺ»
    • ¸»·¹À̽þÆ
    • Çʸ®ÇÉ
    • ½Ì°¡Æ÷¸£
    • Çѱ¹
    • ´ë¸¸
    • ű¹
    • º£Æ®³²

    Á¦11Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¹éÇ÷±¸ ¼ººÐ äÁý¼ú ½ÃÀå

    • ¼Ò°³
    • µ§¸¶Å©
    • ÀÌÁýÆ®
    • Çɶõµå
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • À̽º¶ó¿¤
    • ÀÌÅ»¸®¾Æ
    • ³×´ú¶õµå
    • ³ªÀÌÁö¸®¾Æ
    • ³ë¸£¿þÀÌ
    • Æú¶õµå
    • īŸ¸£
    • ·¯½Ã¾Æ
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ½ºÆäÀÎ
    • ½º¿þµ§
    • ½ºÀ§½º
    • ÅÍŰ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • ¿µ±¹

    Á¦12Àå °æÀï ±¸µµ

    • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
    • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023³â
    • °æÀï ½Ã³ª¸®¿À ºÐ¼®
    • Àü·« ºÐ¼®°ú Á¦¾È

    ±â¾÷ ¸ñ·Ï

    • Allcells, LLC
    • Asahi Kasei Corporation
    • Beijing Zksk Technology Co. Ltd.
    • Bioivt
    • Caltag Medsystems Limited
    • Charles River Laboratories International, Inc.
    • Discovery Life Sciences
    • Fresenius Se & Co. Kgaa
    • Guangzhou Daji Medical Science and Technology Co. Ltd.
    • Haemonetics Corporation
    • Intelligent Tissue Group
    • Lonza Group Ag
    • Macopharma Sa
    • Medica Spa.
    • Miltenyi BIoTec
    • Precision for Medicine, Inc.
    • Puriblood Medical Co. Ltd.
    • Stemexpress, LLC
    • Terumo BCT
    • Zenbio, Inc.
    BJH 25.01.08

    The Leukapheresis Market was valued at USD 56.21 million in 2023, expected to reach USD 61.62 million in 2024, and is projected to grow at a CAGR of 9.71%, to USD 107.58 million by 2030.

    Leukapheresis, a specialized procedure to separate leukocytes (white blood cells) from the blood, plays a critical role in therapeutic and research settings, particularly in treating conditions like leukemia and lymphoma and for harvesting cells for advanced therapies like CAR T-cell therapies. Its necessity arises primarily from the need for precise blood component separation for both immediate therapeutic interventions and the cultivation of cells in burgeoning cell-based research. The application of leukapheresis spans clinical, commercial, and research domains, with end-use in hospitals, research institutes, and biotechnology companies. Market growth is fueled by rising incidences of blood-related disorders, advancements in cell-based therapies, and an increasing focus on personalized medicine. Emerging opportunities lie in leveraging improvements in apheresis technologies and the integration of AI for process optimization. The proliferation of biotech startups focusing on cell therapy further underscores potential market expansion. However, challenges include high procedure costs, regulatory complexities, and limited awareness in developing regions. Innovation opportunities exist in enhancing automation and efficiency of leukapheresis devices, improving donor safety protocols, and reducing operational costs. The market is dynamic, characterized by rapid technological advancements and collaboration between healthcare providers and biotechnology firms. Despite the challenges, extensive R&D investment in expanding the scope and efficiency of apheresis technologies and cross-sector partnerships can foster market growth. Companies may capitalize on the developing precision medicine sector by innovating in data analytics and machine learning to refine patient-selection strategies and personalize treatment outcomes. Future research could focus on cost-effective, scalable leukapheresis techniques and broader educational initiatives to heighten awareness in underpenetrated markets. As the market navigates these complexities, strategic positioning in emerging economies, technological enhancements, and compliance with evolving regulatory standards will be crucial for sustained growth.

    KEY MARKET STATISTICS
    Base Year [2023] USD 56.21 million
    Estimated Year [2024] USD 61.62 million
    Forecast Year [2030] USD 107.58 million
    CAGR (%) 9.71%

    Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Leukapheresis Market

    The Leukapheresis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

    • Market Drivers
      • Increasing application in cancer therapy
      • Demand for leukapheresis in clinical research
      • Growth in initiatives for blood donations
    • Market Restraints
      • High cost of procedure
    • Market Opportunities
      • Focus and investment in R&D activities
      • Leukapheresis for CAR or Adoptive Cell Therapy
    • Market Challenges
      • Potential issues related to leukapheresis including discomfort, redness, and bruising

    Porter's Five Forces: A Strategic Tool for Navigating the Leukapheresis Market

    Porter's five forces framework is a critical tool for understanding the competitive landscape of the Leukapheresis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

    PESTLE Analysis: Navigating External Influences in the Leukapheresis Market

    External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Leukapheresis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

    Market Share Analysis: Understanding the Competitive Landscape in the Leukapheresis Market

    A detailed market share analysis in the Leukapheresis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

    FPNV Positioning Matrix: Evaluating Vendors' Performance in the Leukapheresis Market

    The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Leukapheresis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

    Strategy Analysis & Recommendation: Charting a Path to Success in the Leukapheresis Market

    A strategic analysis of the Leukapheresis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

    Key Company Profiles

    The report delves into recent significant developments in the Leukapheresis Market, highlighting leading vendors and their innovative profiles. These include Allcells, LLC, Asahi Kasei Corporation, Beijing Zksk Technology Co. Ltd., Bioivt, Caltag Medsystems Limited, Charles River Laboratories International, Inc., Discovery Life Sciences, Fresenius Se & Co. Kgaa, Guangzhou Daji Medical Science and Technology Co. Ltd., Haemonetics Corporation, Intelligent Tissue Group, Lonza Group Ag, Macopharma Sa, Medica Spa., Miltenyi Biotec, Precision for Medicine, Inc., Puriblood Medical Co. Ltd., Stemexpress, LLC, Terumo BCT, and Zenbio, Inc..

    Market Segmentation & Coverage

    This research report categorizes the Leukapheresis Market to forecast the revenues and analyze trends in each of the following sub-markets:

    • Based on Type, market is studied across Leukapheresis Devices and Leukapheresis Disposables. The Leukapheresis Devices is further studied across Centrifugal Devices and Membrane Separators.
    • Based on Application, market is studied across Research Applications and Therapeutic Applications.
    • Based on End-User, market is studied across Academic & Research Institutes, Blood Component Providers & Blood Centers, Contract Research Organizations, Hospitals & Transfusion Centers, and Pharmaceutical & Biotechnology Companies.
    • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

    The report offers a comprehensive analysis of the market, covering key focus areas:

    1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

    2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

    3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

    4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

    5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

    The report also answers critical questions to aid stakeholders in making informed decisions:

    1. What is the current market size, and what is the forecasted growth?

    2. Which products, segments, and regions offer the best investment opportunities?

    3. What are the key technology trends and regulatory influences shaping the market?

    4. How do leading vendors rank in terms of market share and competitive positioning?

    5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

    Table of Contents

    1. Preface

    • 1.1. Objectives of the Study
    • 1.2. Market Segmentation & Coverage
    • 1.3. Years Considered for the Study
    • 1.4. Currency & Pricing
    • 1.5. Language
    • 1.6. Stakeholders

    2. Research Methodology

    • 2.1. Define: Research Objective
    • 2.2. Determine: Research Design
    • 2.3. Prepare: Research Instrument
    • 2.4. Collect: Data Source
    • 2.5. Analyze: Data Interpretation
    • 2.6. Formulate: Data Verification
    • 2.7. Publish: Research Report
    • 2.8. Repeat: Report Update

    3. Executive Summary

    4. Market Overview

    5. Market Insights

    • 5.1. Market Dynamics
      • 5.1.1. Drivers
        • 5.1.1.1. Increasing application in cancer therapy
        • 5.1.1.2. Demand for leukapheresis in clinical research
        • 5.1.1.3. Growth in initiatives for blood donations
      • 5.1.2. Restraints
        • 5.1.2.1. High cost of procedure
      • 5.1.3. Opportunities
        • 5.1.3.1. Focus and investment in R&D activities
        • 5.1.3.2. Leukapheresis for CAR or Adoptive Cell Therapy
      • 5.1.4. Challenges
        • 5.1.4.1. Potential issues related to leukapheresis including discomfort, redness, and bruising
    • 5.2. Market Segmentation Analysis
      • 5.2.1. Type: Increasing use of leukapheresis devices for efficient separation of white blood cells
      • 5.2.2. Application: Rising application of leukapheresis in therapeutics for improved patient outcome
      • 5.2.3. End-User: Proliferating use of leukapheresis devices by blood component providers & blood centers
    • 5.3. Porter's Five Forces Analysis
      • 5.3.1. Threat of New Entrants
      • 5.3.2. Threat of Substitutes
      • 5.3.3. Bargaining Power of Customers
      • 5.3.4. Bargaining Power of Suppliers
      • 5.3.5. Industry Rivalry
    • 5.4. PESTLE Analysis
      • 5.4.1. Political
      • 5.4.2. Economic
      • 5.4.3. Social
      • 5.4.4. Technological
      • 5.4.5. Legal
      • 5.4.6. Environmental

    6. Leukapheresis Market, by Type

    • 6.1. Introduction
    • 6.2. Leukapheresis Devices
      • 6.2.1. Centrifugal Devices
      • 6.2.2. Membrane Separators
    • 6.3. Leukapheresis Disposables

    7. Leukapheresis Market, by Application

    • 7.1. Introduction
    • 7.2. Research Applications
    • 7.3. Therapeutic Applications

    8. Leukapheresis Market, by End-User

    • 8.1. Introduction
    • 8.2. Academic & Research Institutes
    • 8.3. Blood Component Providers & Blood Centers
    • 8.4. Contract Research Organizations
    • 8.5. Hospitals & Transfusion Centers
    • 8.6. Pharmaceutical & Biotechnology Companies

    9. Americas Leukapheresis Market

    • 9.1. Introduction
    • 9.2. Argentina
    • 9.3. Brazil
    • 9.4. Canada
    • 9.5. Mexico
    • 9.6. United States

    10. Asia-Pacific Leukapheresis Market

    • 10.1. Introduction
    • 10.2. Australia
    • 10.3. China
    • 10.4. India
    • 10.5. Indonesia
    • 10.6. Japan
    • 10.7. Malaysia
    • 10.8. Philippines
    • 10.9. Singapore
    • 10.10. South Korea
    • 10.11. Taiwan
    • 10.12. Thailand
    • 10.13. Vietnam

    11. Europe, Middle East & Africa Leukapheresis Market

    • 11.1. Introduction
    • 11.2. Denmark
    • 11.3. Egypt
    • 11.4. Finland
    • 11.5. France
    • 11.6. Germany
    • 11.7. Israel
    • 11.8. Italy
    • 11.9. Netherlands
    • 11.10. Nigeria
    • 11.11. Norway
    • 11.12. Poland
    • 11.13. Qatar
    • 11.14. Russia
    • 11.15. Saudi Arabia
    • 11.16. South Africa
    • 11.17. Spain
    • 11.18. Sweden
    • 11.19. Switzerland
    • 11.20. Turkey
    • 11.21. United Arab Emirates
    • 11.22. United Kingdom

    12. Competitive Landscape

    • 12.1. Market Share Analysis, 2023
    • 12.2. FPNV Positioning Matrix, 2023
    • 12.3. Competitive Scenario Analysis
      • 12.3.1. SCTbio Partners With Cyto-Care To Improve Cell Therapy Cryopreservation
      • 12.3.2. Akadeum Launches T Cell Activation and Expansion Using Positive Selection and Expands Leukopak Cell Isolation Product Lines
      • 12.3.3. Fresenius Kabi Launches Single-Needle Option for the Amicus Extracorporeal Photopheresis Protocol
    • 12.4. Strategy Analysis & Recommendation

    Companies Mentioned

    • 1. Allcells, LLC
    • 2. Asahi Kasei Corporation
    • 3. Beijing Zksk Technology Co. Ltd.
    • 4. Bioivt
    • 5. Caltag Medsystems Limited
    • 6. Charles River Laboratories International, Inc.
    • 7. Discovery Life Sciences
    • 8. Fresenius Se & Co. Kgaa
    • 9. Guangzhou Daji Medical Science and Technology Co. Ltd.
    • 10. Haemonetics Corporation
    • 11. Intelligent Tissue Group
    • 12. Lonza Group Ag
    • 13. Macopharma Sa
    • 14. Medica Spa.
    • 15. Miltenyi Biotec
    • 16. Precision for Medicine, Inc.
    • 17. Puriblood Medical Co. Ltd.
    • 18. Stemexpress, LLC
    • 19. Terumo BCT
    • 20. Zenbio, Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦